eligibility_summary
Adults ≥18 with multiple myeloma, measurable disease per IMWG, ECOG ≤2, triple-class refractory (to ≥1 proteasome inhibitor, ≥1 IMiD, and ≥1 anti‑CD38), and ≥1 therapy after TCR. Excludes acute plasma cell leukemia, amyloidosis, smoldering MM, transplant within 12 weeks or active GVHD, active malignancy in past 3 years (except basal/squamous skin cancer or carcinoma in situ), or investigational drug within 30 days.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
NCT05932290 (Pfizer) is a completed observational comparative-effectiveness study in triple-class refractory relapsed/refractory multiple myeloma. Intervention: Elranatamab (PF-06863135), a bispecific T‑cell–engaging antibody (immunotherapy) targeting BCMA×CD3. Mechanism: binds BCMA (TNFRSF17) on malignant plasma cells and CD3 on T cells, forming an immune synapse that activates and redirects T‑cell cytotoxicity, leading to killing of BCMA+ myeloma cells and cytokine-mediated antitumor effects. Comparator: real‑world standard‑of‑care therapies. Cells/pathways targeted: BCMA-expressing plasma cells, CD3+ T lymphocytes, BCMA signaling on myeloma cells and T‑cell receptor/CD3 activation in T cells.